Fujian Key Laboratory of Innate Immune Biology, Biomedical Research Center of South China, College of Life Science, Fujian Normal University, Fuzhou 350117, China.
Int J Mol Sci. 2023 Aug 18;24(16):12916. doi: 10.3390/ijms241612916.
Decoy receptor 3 (DcR3), a soluble glycosylated protein in the tumor necrosis factor receptor superfamily, plays a role in tumor and inflammatory diseases. Sepsis is a life-threatening organ dysfunction caused by the dysregulation of the response to infection. Currently, no specific drug that can alleviate or even cure sepsis in a comprehensive and multi-level manner has been found. DcR3 is closely related to sepsis and considerably upregulated in the serum of those patients, and its upregulation is positively correlated with the severity of sepsis and can be a potential biomarker for diagnosis. DcR3 alone or in combination with other markers has shown promising results in the early diagnosis of sepsis. Furthermore, DcR3 is a multipotent immunomodulator that can bind FasL, LIGHT, and TL1A through decoy action, and block downstream apoptosis and inflammatory signaling. It also regulates T-cell and macrophage differentiation and modulates immune status through non-decoy action; therefore, DcR3 could be a potential drug for the treatment of sepsis. The application of DcR3 in the treatment of a mouse model of sepsis also achieved good efficacy. Here, we introduce and discuss the progress in, and suggest novel ideas for, research regarding DcR3 in the diagnosis and treatment of sepsis.
诱饵受体 3（DcR3）是肿瘤坏死因子受体超家族中的一种可溶性糖基化蛋白，在肿瘤和炎症性疾病中发挥作用。脓毒症是一种危及生命的器官功能障碍，由感染反应失调引起。目前，尚未发现能够全面、多层次缓解甚至治愈脓毒症的特定药物。DcR3 与脓毒症密切相关，在患者血清中显著上调，其上调与脓毒症的严重程度呈正相关，可作为潜在的诊断生物标志物。DcR3 单独或与其他标志物联合使用，在脓毒症的早期诊断中显示出良好的效果。此外，DcR3 是一种多效免疫调节剂，可通过诱饵作用结合 FasL、LIGHT 和 TL1A，阻断下游凋亡和炎症信号。它还通过非诱饵作用调节 T 细胞和巨噬细胞分化，并调节免疫状态；因此，DcR3 可能成为治疗脓毒症的潜在药物。DcR3 在脓毒症小鼠模型中的应用也取得了良好的疗效。在这里，我们介绍并讨论了 DcR3 在脓毒症诊断和治疗方面的研究进展，并提出了一些新的思路。
